Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, is dedicated to developing innovative therapies for rare diseases. Founded in 2002, the company has made significant strides in the industry, particularly in the treatment of sickle cell disease. Emmaus is renowned for its flagship product, Endari, which is the first FDA-approved treatment specifically for patients aged five and older with this condition. The unique formulation of L-glutamine in Endari helps reduce the frequency of painful crises and hospitalisations, setting it apart in the market. With a strong commitment to research and development, Emmaus Life Sciences continues to expand its operational reach, aiming to improve the quality of life for patients globally. The company’s dedication to addressing unmet medical needs positions it as a notable player in the biopharmaceutical landscape.
DitchCarbon Score
How does Emmaus Life Sciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Emmaus Life Sciences, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Emmaus Life Sciences, Inc.'s reported carbon emissions
Emmaus Life Sciences, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As such, Emmaus Life Sciences does not appear to have established any formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. In the context of the industry, many companies are increasingly adopting science-based targets and sustainability practices to mitigate climate change impacts. However, without specific emissions data or commitments, Emmaus Life Sciences remains outside this trend.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Emmaus Life Sciences, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
